Toxicities of CD19 CAR-T Cell Immunotherapy

American Journal of Hematology - United States
doi 10.1002/ajh.25445
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

High Rate of Durable Complete Remission in Follicular Lymphoma After Cd19 Car-T Cell Immunotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

CAR-T Cells Beyond CD19, UnCAR-Ted Territory

American Journal of Hematology
Hematology
2019English

Improving CAR T Cell Immunotherapy–mediated Remissions for Pediatric Leukemia

Journal of Clinical Investigation
Medicine
2019English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors

Science China Life Sciences
GeneticsMolecular BiologyEnvironmental ScienceBiochemistryBiological SciencesAgricultural
2016English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Outcomes of Patients With Large B‐Cell Lymphomas and Progressive Disease Following CD19‐Specific CAR T‐Cell Therapy

American Journal of Hematology
Hematology
2019English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy